Literature DB >> 15995903

Antipsychotic and antidepressive effects of second generation antipsychotics: two different pharmacological mechanisms?

Hans-Jürgen Möller1.   

Abstract

Second generation antipsychotics display antidepressive effects in schizophrenic patients that are more pronounced than those of traditional neuroleptics and that go beyond antidepressive effects secondary to the reduction of positive symptoms. The antidepressive potential of second generation antipsychotics is presumably related to their pharmacological mechanisms, which differ from those of traditional neuroleptics. Among others, 5-HT(2A) antagonism is of special relevance for most of the new antipsychotics in this respect. But also special interactions with the dopaminergic system, as is the case with amisulpride and aripiprazole, or noradrenalin- and/or serotonin-reuptake-inhibition, as with ziprasidone and zotepine, should be considered. It can be summarised that the antipsychotic and antidepressive effects of second generation antipsychotics are mostly based on different pharmacological mechanisms. This might be especially true for direct antidepressive effects, i. e. antidepressive effects that are not mediated by the reduction of positive symptoms.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15995903     DOI: 10.1007/s00406-005-0587-5

Source DB:  PubMed          Journal:  Eur Arch Psychiatry Clin Neurosci        ISSN: 0940-1334            Impact factor:   5.270


  126 in total

1.  In vivo characteristics of dopamine D2 receptor occupancy by amisulpride in schizophrenia.

Authors:  J L Martinot; M L Paillère-Martinot; M F Poirier; M H Dao-Castellana; C Loc'h; B Mazière
Journal:  Psychopharmacology (Berl)       Date:  1996-03       Impact factor: 4.530

2.  D4 dopamine receptor binding affinity does not distinguish between typical and atypical antipsychotic drugs.

Authors:  B L Roth; S Tandra; L H Burgess; D R Sibley; H Y Meltzer
Journal:  Psychopharmacology (Berl)       Date:  1995-08       Impact factor: 4.530

3.  In vivo effects of olanzapine on striatal dopamine D(2)/D(3) receptor binding in schizophrenic patients: an iodine-123 iodobenzamide single-photon emission tomography study.

Authors:  S Dresel; T Mager; B Rossmüller; E Meisenzahl; K Hahn; H J Möller; K Tatsch
Journal:  Eur J Nucl Med       Date:  1999-08

4.  The effects of antipsychotic drugs on serotonergic activity in the rat hippocampus.

Authors:  K Antoniou; S Bekris; M Saranti; P Stathis; M Rimikis; Z Papadopoulou-Daifoti
Journal:  Eur Neuropsychopharmacol       Date:  2000-09       Impact factor: 4.600

5.  Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile.

Authors:  A W Schmidt; L A Lebel; H R Howard; S H Zorn
Journal:  Eur J Pharmacol       Date:  2001-08-17       Impact factor: 4.432

6.  Psychopharmacological profile of amisulpride: an antipsychotic drug with presynaptic D2/D3 dopamine receptor antagonist activity and limbic selectivity.

Authors:  G Perrault; R Depoortere; E Morel; D J Sanger; B Scatton
Journal:  J Pharmacol Exp Ther       Date:  1997-01       Impact factor: 4.030

Review 7.  State of the art of drug treatment of schizophrenia and the future position of the novel/atypical antipsychotics.

Authors:  H J Möller
Journal:  World J Biol Psychiatry       Date:  2000-10       Impact factor: 4.132

8.  Effects of neuroleptics displaying antidepressant activity on behavior of rats in the forced swimming test.

Authors:  Z Górka; K Janus
Journal:  Pharmacol Biochem Behav       Date:  1985-08       Impact factor: 3.533

Review 9.  New drugs for the treatment of schizophrenia.

Authors:  H Y Meltzer
Journal:  Psychiatr Clin North Am       Date:  1993-06

10.  Depressive syndromes in schizophrenic patients under neuroleptic therapy. ANI Study Group Berlin, Düsseldorf, Göttingen, Munich, Federal Republic of Germany.

Authors:  B Bandelow; P Müller; U Frick; W Gaebel; M Linden; F Müller-Spahn; A Pietzcker; J Tegeler
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1992       Impact factor: 5.270

View more
  17 in total

1.  Influence of the drug exposure definition on the assessment of the antipsychotic metabolic impact in patients initially treated with mood-stabilizers.

Authors:  Marie Tournier; Bernard Bégaud; Audrey Cougnard; Guy-Robert Auleley; Jean Deligne; Claudine Blum-Boisgard; Anne C M Thiébaut; Hélène Verdoux
Journal:  Br J Clin Pharmacol       Date:  2012-07       Impact factor: 4.335

Review 2.  [Antipsychotic drug-induced changes in metabolism].

Authors:  Julia Engl; Alexander Tschoner; Markus Laimer; Maria Rettenbacher; W Wolfgang Fleischhacker; Josef R Patsch; Christoph Ebenbichler
Journal:  Wien Klin Wochenschr       Date:  2006-05       Impact factor: 1.704

Review 3.  Antidepressive effects of traditional and second generation antipsychotics: a review of the clinical data.

Authors:  Hans-Jürgen Möller
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2005-04       Impact factor: 5.270

Review 4.  Can we really prevent suicide?

Authors:  Maya Schwartz-Lifshitz; Gil Zalsman; Lucas Giner; Maria A Oquendo
Journal:  Curr Psychiatry Rep       Date:  2012-12       Impact factor: 5.285

Review 5.  Adverse effects of atypical antipsychotics in the elderly: a review.

Authors:  Pietro Gareri; Pasquale De Fazio; Salvatore De Fazio; Norma Marigliano; Guido Ferreri Ibbadu; Giovambattista De Sarro
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

Review 6.  Comparative pharmacology of antipsychotics possessing combined dopamine D2 and serotonin 5-HT1A receptor properties.

Authors:  Adrian Newman-Tancredi; Mark S Kleven
Journal:  Psychopharmacology (Berl)       Date:  2011-03-11       Impact factor: 4.530

Review 7.  Do recent efficacy data on the drug treatment of acute bipolar depression support the position that drugs other than antidepressants are the treatment of choice? A conceptual review.

Authors:  Hans-Jürgen Möller; Heinz Grunze; Karl Broich
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2005-08-04       Impact factor: 5.270

Review 8.  [Genetics of weight gain associated with antipsychotic medications].

Authors:  D J Müller; C Peter; I Puls; E J Brandl; U E Lang; J Gallinat; A Heinz
Journal:  Nervenarzt       Date:  2009-05       Impact factor: 1.214

Review 9.  Ziprasidone for the treatment of acute manic or mixed episodes associated with bipolar disorder.

Authors:  Lewis Warrington; Ilise Lombardo; Antony Loebel; Kathleen Ice
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

10.  Evidence for separate diseases?: Stages of one disease or different combinations of symptom dimensions?

Authors:  Heinz Häfner; Wolfram an der Heiden; Kurt Maurer
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2008-06       Impact factor: 5.270

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.